Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple vs Dual Therapy for PONV Prevention in Gynecologic Surgery
NCT05773950Enrolling by invitation
- Sponsor
- Samsung Medical Center
- Start
- Aug 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of fosaprepitant in postoperative nausea and vomiting (PONV) (2 arms), sponsored by Samsung Medical Center. Primary endpoint: Incidence of Postoperative Nausea and Vomiting. Started Aug 2023; status: enrolling by invitation.
02
Drugs
fosaprepitant
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT05773950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05773950.